Redensyl improved hair thickness slightly with no side effects, but no regrowth. Minoxidil provided significant regrowth but caused facial side effects like puffiness.
Teak leaf extract shows potential as a mild hair growth promoter for androgenic alopecia, with similar positive trends to minoxidil but without significant side effects. It can be made at home using dried teak leaves and ethanol, though its effectiveness compared to other treatments like finasteride is debated.
Diffuse thinning is often due to androgenetic alopecia, and DHT blockers like finasteride are recommended. Treatments mentioned include minoxidil, finasteride, dutasteride, and RU58841, with emphasis on starting early and using a holistic approach.
The user experienced reduced hair shedding after three months of injecting 1mg BPC-157 into the scalp, while continuing to use dutasteride and minoxidil. The injections are painful, and the user sometimes switches to injecting into the buttocks.
A 49-year-old is updating on hair regrowth progress using finasteride, minoxidil foam, tretinoin cream, and ketoconazole shampoo. They report thicker, darker hair and reduced scalp itch after switching to minoxidil foam.
A user experienced an allergic reaction, including swollen lymph nodes, to Minoxidil 5% with an aqueous base. Switching to a non-alcohol-based Minoxidil (Prolox 5%) resolved the allergies.
The conversation discusses a patent for using topical resveratrol and melatonin to treat androgenetic alopecia (AGA) and also mentions interest in topical sulforaphane as a treatment.
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.
User experienced rapid thinning on crown, used dutasteride for 3 months with significant improvement. Microneedling and ketoconazole were also used, but no minoxidil or finasteride.
PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.
Cecred hair drops, containing keratin and biotin, are questioned for their effectiveness compared to proven treatments like minoxidil. Users express skepticism, suggesting deceptive marketing and the possibility of undisclosed use of other treatments like finasteride.
A new hair growth product claims to use apple stem cells, plant collagen, and bamboo leaf extract, with a 120-day money-back guarantee. Some users are skeptical, noting the product's marketing alongside other treatments like Minoxidil, finasteride, and red light therapy.
The user is experiencing one-sided diffuse thinning and has been using finasteride and liquid minoxidil for 4-5 years with minimal results. They are considering whether to save for a hair transplant or address scalp sensitivity and irritation first.
Feeding bacteria-free mice with Lactobacillus murinus worsened hair loss, but a regular diet with biotin stopped it. The conversation suggests gut bacteria and diet may influence hair loss, with some skepticism and discussion about other factors like DHT and genetics.
Minoxidil can prevent hair follicle miniaturization, not just stimulate hair growth. Finasteride and dutasteride don't work for everyone, suggesting DHT may not be the sole cause of hair loss; hair loss could be due to multiple factors, including autoimmune conditions.
A trans woman is using 10 mg oral minoxidil, dutasteride, and estradiol for hair regrowth and is also doing dermastamping despite the pain. Users discuss the benefits of dermastamping for serum absorption and hair follicle stimulation, with some expressing surprise at the high minoxidil dosage.
The user is concerned about hair loss and is using treatments like dutasteride, microneedling, and topical finasteride, while considering adding RU58841. They are also using Minoxidil on the temples and are worried about testosterone-related hair loss.
A user proposed genetically engineering scalp stem cells to stop androgen receptors from causing hair loss. Others discussed the feasibility, existing research, and potential issues with this approach, including targeting the correct cells and unintended effects.
The user is using finasteride (1 mg daily), topical minoxidil, and microneedling with a derma stamp for hair loss. They reported shedding stopped and new hair growth appeared after a few months, with no side effects.
Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.
Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.
A Silicon Valley-backed company aims to cure hair loss. Exciting advancements include mRNA therapies, gene editing, hair cloning, AR degraders, anti-androgens, cell-based rejuvenation, and AI-based drug discovery, with hopes for FDA approval of GT20029 within 10 years.
A 17-year-old is addressing hair loss with finasteride, topical minoxidil, and microneedling. They are considering adding GHK-Cu to their regimen, but others advise caution with finasteride due to age.
A 22-year-old is frustrated with ongoing hair loss despite using treatments like topical minoxidil, finasteride, microneedling, oral dutasteride, and oral minoxidil. Their dermatologist suggests treating scalp inflammation with oral tretinoin and using exosomes for alopecia.
Salicylic acid in Nioxin shampoo may reduce minoxidil effectiveness by inhibiting sulfotransferase activity, potentially causing hair loss. Users suggest stopping salicylic acid use or trying alternative treatments like high-concentration tretinoin or medicated minoxidil/finasteride shampoos.
Minoxidil may inhibit androgen receptors and affect hormonal pathways, potentially explaining its effectiveness in treating androgenetic alopecia (AGA). Users discuss its varying effectiveness on scalp versus facial hair and note fewer side effects with topical use compared to oral.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.